In a world where the ingredients are scarce and often in the most extreme conditions, some of the most potent herbal remedies are made in India.
The United States has a long history of exporting Indian medicines, and the World Health Organization (WHO) has even designated India the number one country for the use of its drugs.
The Indian government has recently expanded its own domestic herbal and medicinal products.
India is home to a multitude of herbs and traditional medicine products, including ayurvedic medicines, gourds, herbs, botanicals and plants.
The World Health Organisation (WHO), however, notes that it is the most vulnerable country in terms of access to medicines, with one-third of all countries having less than 10% access to essential medicines, such as essential medicines for malaria, tuberculosis and diarrhoea.
It is a problem that has been worsened by the high price of drugs, which are sold at a prohibitively high price in India and often out of reach for most people.
A group of activists in India are calling for an urgent overhaul of the health sector to reduce the cost of essential medicines in the country.
Their petition aims to end the monopoly of Indian pharmaceutical companies and to bring about universal access to the medicines needed to live a healthy life.
According to the WHO, there are currently around 6.6 billion people living in India who lack access to medicine.
The group believes that access to vital medicines, including the medicines that will prevent and treat chronic diseases, is a fundamental human right and that the system of international trade is not helping in this regard.
The petition seeks to ensure that the medicines are manufactured and sold in India in the way that it should be, and that Indians can access these essential medicines.
India has a thriving private pharmaceutical sector and the government of India has committed to the elimination of the black market in pharmaceuticals, which the group says has resulted in the creation of the Indian Pharmaceutical Industry Development Fund (IPIDF), an entity that will distribute medicines to those who need them.
In 2017, the government announced an investment of $1 billion in the IPIDF, to support development of the pharmaceutical industry in India, which aims to provide a robust, secure and competitive supply of medicines.
In September, the World Bank announced a $250 million loan to the Indian government to create the IP IDF.
The initiative aims to create a pool of funds to finance a private sector entity to make medicines in India affordable to all Indians.
The IPID is the only national organisation in the world to have such a fund, which was launched in January 2018.
The petition comes after a similar petition was launched by the Indian Medical Association (IMA) in 2016, calling for a ban on sale of essential medicine in India for the betterment of health and safety.
The Indian Medical Society (IMS) in a report released in January 2017 said the country’s current health care system is unsustainable and needs a drastic overhaul.
It noted that many of the basic healthcare services are not accessible to the poor.
It said that access is also very limited to those in rural areas, and most of these services are provided by the private sector.
According the IMS report, India currently ranks 12th out of 178 countries in terms in access to healthcare services.
The IMS said that it was concerned that the private pharmaceutical industry was currently in the process of acquiring all essential medicines from abroad.
India was the first country to sign the Comprehensive Drug Agreement with the European Union in March 2019, which effectively closed the gap between the cost and availability of medicines in Europe.
The IMS also called on the government to ensure universal access, particularly for people with chronic diseases.